Dr. Ian Wilkinson joins mAbsolve as Chief Scientific Officer
Starting today Dr. Ian Wilkinson joins mAbsolve as Chief Scientific Officer, having been a Founder and non-executive Director ...
Read More Prof. Geoff Hale to present at Antibody Drug Development Summit 2021
Prof. Geoff Hale, CEO of mAbsolve, will present on our novel STR Fc silencing technology at the upcoming ...
Read More mAbsolve Files International Patent Application
mAbsolve has today filed an international patent application PCT/GB2021/051233 on its novel Fc silencing technology.
Read More Prof. Geoff Hale to present at Mastering Immunity Europe 2021
Prof. Geoff Hale, CEO of mAbsolve, will present on our novel STR Fc silencing technology at the upcoming ...
Read More Prof. Geoff Hale to present at Biologics Symposium 2020
Prof. Geoff Hale, CEO of mAbsolve, will present on our novel STR Fc silencing technology at the upcoming ...
Read More Novalgen licenses mAbsolve’s technology to improve the safety of therapeutic antibodies
A new generation of antibody variant developed by mAbsolve has been licensed to Novalgen for evaluation in their ...
Read More ONA Therapeutics sign licence to STR technology
The STR antibody technology developed by mAbsolve for truly silenced antibodies has been licensed to ONA Therapeutics for ...
Read More mAbsolve launches STR, a novel Fc silencing technology available to licence
After a period of research and development mAbsolve today announces the formal launch of its Fc silencing technology ...
Read More mAbsolve files patent on novel Fc silencing technology
mAbsolve has today filed a patent on its novel Fc silencing technology, GB2007613.9.
Read More - « Previous
- 1
- 2
- 3
- 4
- Next »